ImprimisRx’s Patented Klarity-C® 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 OptometristsGlobeNewsWire • 06/18/20
Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine ServicesGlobeNewsWire • 03/24/20
Harrow Health, Inc. (HROW) CEO Mark Baum on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/13/20
ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA)GlobeNewsWire • 03/03/20
Implied Volatility Surging for Harrow Health (HROW) Stock OptionsZacks Investment Research • 02/03/20
Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/14/19
Earnings Preview: Harrow Health (HROW) Q3 Earnings Expected to DeclineZacks Investment Research • 11/06/19
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of DirectorsGlobeNewsWire • 10/23/19
Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019GlobeNewsWire • 10/08/19
ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology MeetingGlobeNewsWire • 10/08/19